ANNEE 2017
Publié le 30/03/2018 à 16h06
Abadie D, Essilini A, Montastruc F, Fulda V, Gouraud A, Yéléhé-Okouma M, Jean-Pastor M, Montastruc JL. Drug-induced panic attacks : analysis of cases registered in the French pharmacovigilance database. J Psychiatr Res. 2017 ;90:60-66.
Allain N, Leven C, Falissard B, Allain JS, Batail JM, Polard E, Montastruc F, Drapier D, Naudet F. Manic switches induced by antidepressants : an umbrella review comparing randomized controlled trials and observational studies. Acta Psychiatr Scand. 2017 ;135:106-116.
Beau AB, Tauber M, Chollet C, Hurault-Delarue C, Bouilhac C, Montastruc JL, Lacroix I, Damase-Michel C. A contemporary description of French newborns’ growth using the Efemeris cohort. Arch Pediatr. 2017 ;24:424-431.
Beau AB, Didier A, Hurault-Delarue C, Montastruc JL, Lacroix I, Damase-Michel C. Prescription of asthma medications before and during pregnancy in France : An observational drug study using the EFEMERIS database. J Asthma. 2017 ;54:258-264.
Benevent J, Montastruc F, Damase-Michel C. The importance of pharmacoepidemiology in pregnancy-implications for safety. Expert Opin Drug Saf. 2017 ;16:1181-90.
Benevent J, Bouton J, Damase-Michel C. Effets indésirables gynécologiques des anti-facteur de nécrose tumorale ; Gynaecological side effects of TNF-inhibitors. Rep Gyn End. 2017 ;19:146-52.
Bondon-Guitton E, Mourgues T, Rousseau V, Cousty S, Cottin J, Drablier G, Micallef J, Montastruc JL. Gingival bleeding, a possible "serious" adverse drug reaction : An observational study in the French PharmacoVigilance Database. J Clin Periodontol. 2017 ;44:898-904.
Bouvenot G, Sassard J, Montastruc JL. For an optimal use of fixed drug combinations. Therapie. 2017 ;72:665-668.
Cabarrot A, Montastruc JL, Chebane L, Rousseau V, Bondon-Guitton E, Moulis F, Durrieu G, Bagheri H, Montastruc F. Neurological and Digestive Bleeding with Direct Oral Anticoagulants versus Vitamin K Antagonists : the differences do not stop there ! A pharmacovigilance study. Pharmacol Res. 2017 ;118:119-120.
Caillet C, Sichanh C, Assemat G, Malet-Martino M, Sommet A, Bagheri H, Sengxeu N, Mongkhonmath N, Mayxay M, Syhakhang L, Lapeyre-Mestre M, Newton PN, Roussin A. Role of Medicines of Unknown Identity in Adverse Drug Reaction-Related Hospitalizations in Developing Countries : Evidence from a Cross-Sectional Study in a Teaching Hospital in the Lao People’s Democratic Republic. Drug Saf. 2017 ;40:809-821.
Chatelet JN, Auffret M, Combret S, Bondon-Guitton E, Lambert M, Gautier S. Hydroxychloroquine-induced hearing loss : First case of positive rechallenge and analysis of the French pharmacovigilance database. Rev Med Interne. 2017 ;38:340-343.
Couture G, Delzor F, Bagheri H, Micallef J, Ruyssen-Witrand A, Laroche M. First cases of calcium pyrophosphate deposition disease after zoledronic acid therapy. Joint Bone Spine. 2017 ;84:213-215.
Durrieu G, Jacquot J, Baudrin D, Mège M, Rousseau V, Bagheri H, Bondon-Guitton E, Abadie D, Montastruc F, Bismuth M, Oustric S, Montastruc JL. Improving adverse drug reaction reporting by general practitioners through clinical research assistants visits. Therapie. 2016 ;72:351-355.
Faillie JL, Ferrer P, Gouverneur A, Driot D, Berkemeyer S, Vidal X, Martínez-Zapata MJ, Huerta C, Castells X, Rottenkolber M, Schmiedl S, Sabaté M, Ballarín E, Ibáñez L. A new risk of bias checklist applicable to randomized trials, observational studies, and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events. J Clin Epidemiol. 2017 ;86:168-175.
Formoso G, Font-Pous M, Ludwig WD, Phizackerley D, Bijl D, Erviti D, Pospisilova B, Montastruc JL. Drug information by public health and regulatory institutions : results of an 8-coutry survey in Europe. Health Policy. 2017:121 ;257-264.
16. Gautier Y, Montastruc F. Pharmacovigilance, une consultation pour les pathologies médicamenteuses. Le Moniteur des Pharm. 2017 ;3158:19.
Gicquel C, Moulis F, Chenaf C, Gouraud A, Drici M, Bondon-Guitton E, Montastruc F, Montastruc JL. Duloxetine and gingival bleeding : a case-report and reviews of the French and World PharmacoVigilance Databases and literature. Eur J Clin Pharmacol. 2017 ;73:1197-98.
Graner S, Svensson T, Beau AB, Damase-Michel C, Engeland A, Furu K, Hviid A, Haberg SE, Molgaard-Nielsen D, Pasternak B, Kieler H. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations : population based European register study. BMJ. 2017 ;356:j629.
Humbert X, Dolladille C, Sassier M, Valnet-Rabier MB, Vial T, Guitton E, Page A, Sole E, Auriche P, Coquerel A, Alexandre J, Fedrizzi S. Fibrates and risk of venous thromboembolism : Case/no-case study in French pharmacovigilance database. Therapie. 2017 ;72:677-682.
Hurault-Delarue C, Chouquet C, Savy N, Lacroix I, Beau AB, Montastruc JL, Damase-Michel C. Interest of the trajectory method for the evaluation of outcomes after in utero drug exposure : example of anxiolytics and hypnotics. Pharmacoepidemiol Drug Saf. 2017 ;26:561-569.
Linselle M, Sommet A, Bondon-Guitton E, Moulis F, Durrieu G, Benevent J, Rousseau V, Chebane L, Bagheri H, Montastruc F, Montastruc JL. Can drugs induce or aggravate Sleep Apneas ? A case non case Study in Vigibase®, the WHO Pharmacovigilance Database. Fundam Clin Pharmacol. 2017 ;31:359-366.
Molinier A, Palmaro A, Rousseau V, Sommet A, Bourrel R, Montastruc JL, Bagheri H. Does substitution of brand name medications by generics differ between pharmacotherapeutic classes ? A population-based cohort study in France. Eur J Clin Pharmacol. 2017.73 ;471-77.
Montastruc F, Benevent J, Rousseau V, Chebane L, Bondon‐Guitton E, Durrieu D, Montastruc JL, Sommet A. Statins and diabetes : Is there any difference between the different statins ?. Pharmacoepidemiol Drug Saf. 2017 ;26:1296-1297.
Montastruc F, Moulis F, Araujo M, Chebanne L, Rascol O, Montastruc JL. Ergot and non-ergot dopamine agonists and heart failure in patients with parkinson’s disease. Eur Jour Clin Phar. 2017 ;73:99-103.
Montastruc F, Sommet A, Montastruc JL. Concomitant medications and obstructive sleep apnoea. Br J Clin Pharmacol. 2017 ;83:2315-2316.
Montastruc J, Marque P, Moulis F, Bourg V, Lambert V, Durrieu G, Montastruc JL, Montastruc F. Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy : a pharmaco-epidemiological study in VigiBase. Dev Med Child Neurol. 2017 ;59:329-334.
Montastruc JL, Durrieu G, Lacroix I, Lapeyre-Mestre M, Damase-Michel C, Bagheri H, Sommet A. Quelle Pharmacovigilance pour les vaccins ?. Bull. Acad. Natle. Mèd. Publi 2016. 2017 ;200:35.
Moulis F, Rousseau V, Abadie D, Masmoudi K, Micallef J, Vigier C, Pierre S, Dautriche A, Montastruc F, Montastruc JL. Serious adverse drug reactions with tramadol reported to the French pharmacovigilance database between 2011 and 2015.Therapie. 2017 ;72:615-624.
Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MJ, Day CP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernández N, Ibáñez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watkins PB, Floratos A, Shen Y, Nelson MR, Urban TJ, Daly AK ; International DILI consortium (iDILIC), Drug-induced liver injury network (DILIN) investigators and International Serious Adverse Events Consortium (iSAEC). Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study. Gastroenterology. 2017 ;152:1078-1089.
Nguyen TTH, Pariente A, Montastruc JL, Lapeyre-Mestre M, Rousseau V, Rascol O, Bégaud B, Montastruc F. An original pharmacoepidemiologic - pharmacodynamic method : application to antipsychotic-induced movement disorders. Br J Clin Pharmacol. 2017 ;83:612-622.
Ojero-Senard A, Benevent J, Bondon-Guitton E, Durrieu G, Chebane L, Araujo M, Montastruc F, Montastruc JL. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology. 2017 ;234:3075-81.
Patras de Campaigno E, Kebir I, Montastruc JL, Rueter M, Maret D, Lapeyre-Mestre M, Sallerin B, Despas F. Drug-Induced Dental Caries : A Disproportionality Analysis Using Data from VigiBase. Drug Saf. 2017 ;40:1249-1258.
Patras de Campaigno E, Bondon-Guitton E, Laurent G, Montastruc F, Montastruc JL, Lapeyre-Mestre M, Despas F. Identification of Cellular targets involved in cardiac failure caused by PKI in oncology : an approach combining Pharmacovigilance and Pharmacodynamics. Br J Clin Pharmacol. 2017 ;83:1544-1555.
Ravoire S, Lang M, Perrin E ; participants of Giens XXXII Round Table No. 6. Audry A, Bilbault P, Chekroun M, Demerville L, Escudier T, Guéroult-Accolas L, Guillot C, Malbezin M, Maugendre P, Micallef J, Molimard M, Montastruc F, Pierron E, Reichardt L, Thiessard F. Advantages and limitations of online communities of patients for research on health products. Therapie. 2017 ;72:135-143.
Ravoire S, Lang M, Perrin E ; les participants à la table ronde N° 6 de Giens XXXII. Audry A, Bilbault P, Chekroun M, Demerville L, Escudier T, Guéroult-Accolas L, Guillot C, Malbezin M, Maugendre P, Micallef J, Molimard M, Montastruc F, Pierron E, Reichardt L, Thiessard F. Intérêts et limites des communautés virtuelles de patients pour la recherche sur les produits de santé. Therapie. 2017 ;72:125-134.
Severino-Freire M, Lamant L, Bagheri H, Mazereeuw-Hautier J, Paul C. Drug eruption with clomifene citrate in a bodybuilder. Ann Dermatol Venereol. 2017 ;144:636-637.
Salgues M, Damase-Michel C, Montastruc JL, Lacroix I. Women’s knowledge of folic acid. Therapie. 2017 ;72:339-343.
Sommet A, Lapeyre-Mestre M. Drug Use and Mortality in Parkinson Disease. J Am Med Dir Assoc. 2017 ;18:989.
Thu Trang D, Cool C, Laffon de Mazieres C, Lapeyre-Mestre M, Montastruc JL, Rascol O, Rolland Y, Sommet A. Mortality and Antipsychotic Drug Use in Elderly Patients With Parkinson Disease in Nursing Homes. J Am Med Dir Assoc. 2017 ;18:791-796.
Partager cette page